In this edition, reduction efforts prevent 3.8 million lung cancer deaths since 1970, first-line combination should be 'new standard' in advanced lung cancer and more. Read the full coverage here: Smoking cessation, reduction efforts prevent 3.8 million lung cancer deaths since 1970 First-line combination should be 'new standard' in advanced lung cancer Only 1 in 5 people treated with immune checkpoint inhibitors respond to therapy 'It can save their lives': Annual lung cancer screening improves cancer detection rate 'Are we giving false hope?': Few hospitalized people with cancer benefit from immunotherapy References: Haslam A, et al. Int J Cancer. 2025;doi:10.1002/ijc.35347. Islami F, et al. CA Cancer J Clin. 2025;doi:10.3322/caac.70005. Kim RY, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.0942. Riaz F, et al. JCO Oncol Pract. 2025;doi:10.1200/OP-24-00788. Yang JCH, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris.

Ver todos los episodios